Liver Expression of Sulphotransferase 2A1 Enzyme Is Impaired in Patients with Primary Sclerosing Cholangitis: Lack of the Response to Enhanced Expression of PXR

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Wunsch, Ewa ^a   Klak, Marta ^a   Wasik, Urszula ^a   Milkiewicz, Malgorzata ^a   Blatkiewicz, Malgorzata ^a   Urasinska, Elzbieta ^a   Barbier, Olivier ^b   Bielicki, Dariusz ^a   Bogdanos, Dimitrios P ^c,d   Elias, Elwyn ^e   Milkiewicz, Piotr ^a,f  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b LAVAL UNIVERSITY   (Canada)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF THESSALY   (Greece)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GENOMIC DNA; MESSENGER RNA; MICRORNA; MICRORNA 378A 5P; PREGNANE X RECEPTOR; SULFOTRANSFERASE; SULFOTRANSFERASE 2A1; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; ALCOHOL SULFOTRANSFERASE; MIRN378 MICRORNA, HUMAN; STEROID RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN TISSUE; ILEAL TISSUE; INTESTINAL TISSUE; LIVER PROTECTION; MALE; NUCLEOTIDE SEQUENCE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PROMOTER REGION; ULCERATIVE COLITIS; WESTERN BLOTTING; CHOLANGITIS, SCLEROSING; GENE EXPRESSION REGULATION; GENETICS; LIVER; LIVER CIRRHOSIS, BILIARY; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; SMALL INTESTINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BASE SEQUENCE; CHOLANGITIS, SCLEROSING; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTESTINE, SMALL; LIVER; LIVER CIRRHOSIS, BILIARY; MALE; MICRORNAS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RECEPTORS, STEROID; RNA, MESSENGER; SULFOTRANSFERASES; YOUNG ADULT;

EID: 84945268615     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/571353     Document Type: Article

References (30)

1. G. M. Hirschfield and E. J. Heathcote, "Cholestasis and cholestatic syndromes, " Current Opinion in Gastroenterology, vol. 25, no. 3, pp. 175-179, 2009.
2. G.M. Hirschfield, T. H. Karlsen, K. D. Lindor, andD. H. Adams, "Primary sclerosing cholangitis, " The Lancet, vol. 382, no. 9904, pp. 1587-1599, 2013.
3. M. Trauner, P. J. Meier, and J. L. Boyer, "Mechanisms of disease: molecular pathogenesis of cholestasis, " The New England Journal of Medicine, vol. 339, no. 17, pp. 1217-1227, 1998.
4. J. L. Boyer, M. Trauner, A. Mennone et al., "Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents, " The American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 290, no. 6, pp. G1124-G1130, 2006.
5. G. Zollner, P. Fickert, D. Silbert et al., "Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis, " Journal of Hepatology, vol. 38, no. 6, pp. 717-727, 2003.
6. G. Zollner, M. Wagner, P. Fickert et al., "Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis, " Liver International, vol. 27, no. 7, pp. 920-929, 2007.
7. M. Trauner, M. Wagner, P. Fickert, and G. Zollner, "Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis, " Journal of Clinical Gastroenterology, vol. 39, no. 4, pp. S111-S124, 2005.
8. G. Zollner, P. Fickert, R. Zenz et al., "Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases, " Hepatology, vol. 33, no. 3, pp. 633-646, 2001.
9. J. Sonoda, W. Xie, J. M. Rosenfeld, J. L. Barwick, P. S. Guzelian, and R. M. Evans, "Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR), " Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 21, pp. 13801-13806, 2002.
10. O. T. Lulu Elekima, C. O. Mills, A. Ahmad et al., "Reduced hepatic content of dehydroepiandrosterone sulphotransferase in chronic liver diseases, " Liver, vol. 20, no. 1, pp. 45-50, 2000.
11. E. Elias and C. O. Mills, "Coordinated defence and the liver, " Clinical Medicine, vol. 7, no. 2, pp. 180-184, 2007.
12. J. Trottier, A. Bialek, P. Caron et al., "Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: A pilot study, " Digestive and Liver Disease, vol. 44, no. 4, pp. 303-310, 2012.
13. K. Geboes, R. Riddell, A. Ost, B. Jensfelt, T. Persson, and R.L. Ofberg, "A reproducible grading scale for histological assessment of inflammation in ulcerative colitis, " Gut, vol. 47, no. 3, pp. 404-409, 2000.
14. M. Milkiewicz, E. Roudier, J. L. Doyle, A. Trifonova, O. Birot, and T. L. Haas, "Identification of a mechanism underlying regulation of the anti-Angiogenic forkhead transcription factor FoxO1 in cultured endothelial cells and ischemic muscle, " The American Journal of Pathology, vol. 178, no. 2, pp. 935-944, 2011.
15. I. Echchgadda, C. S. Song, T. Oh, M. Ahmed, I. J. de la Cruz, and B. Chatterjee, "The xenobiotic-sensing nuclear receptors pregnane X receptor, constitutive androstane receptor, and orphan nuclear receptor hepatocyte nuclear factor 4alpha in the regulation of human steroid-/bile acid-sulfotransferase., " Molecular Endocrinology, vol. 21, no. 9, pp. 2099-2111, 2007.
16. G. Zollner, H.-U. Marschall, M. Wagner, and M. Trauner, "Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations, " Molecular Pharmaceutics, vol. 3, no. 3, pp. 231-251, 2006.
17. S. Iqbal, C. Vickers, and E. Elias, "Drug metabolism in end-stage liver disease. In vitro activities of some phase I and phase II enzymes, " Journal of Hepatology, vol. 11, no. 1, pp. 37-42, 1990.
18. G. Castano, A. Burgueno, T. Fernandez Gianotti, C. J. Pirola, and S. Sookoian, "The influence of common gene variants of the xenobiotic receptor (PXR) in genetic susceptibility to intrahepatic cholestasis of pregnancy, " Alimentary Pharmacology and Therapeutics, vol. 31, no. 5, pp. 583-592, 2010.
19. T. H. Karlsen, B. A. Lie, K. Frey Froslie et al., "Polymorphisms in the steroid and xenobiotic receptor gene influence survival in primary sclerosing cholangitis, " Gastroenterology, vol. 131, no. 3, pp. 781-787, 2006.
20. J. Chai, Y. He, S.-Y. Cai et al., "Elevated hepatic multidrug resistance-Associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-Terminal kinase/stress-Activated protein kinase-signaling pathway, " Hepatology, vol. 55, no. 5, pp. 1485-1494, 2012.
21. J. L. Staudinger, B. Goodwin, S. A. Jones et al., "The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity, " Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 6, pp. 3369-3374, 2001.
22. A. Radominska, K. A. Comer, P. Zimniak, J. Falany, M. Iscan, and C. N. Falany, "Human liver steroid sulphotransferase sulphates bile acids, " Biochemical Journal, vol. 272, no. 3, pp. 597-604, 1990.
23. I. A. Aksoy, V. Sochorova, and R. M. Weinshilboum, "Human liver dehydroepiandrosterone sulfotransferase: nature and extent of individual variation, " Clinical Pharmacology and Therapeutics, vol. 54, no. 5, pp. 498-506, 1993.
24. C. N. Falany, K. A. Comer, T. P. Dooley, and H. Glatt, "Human dehydroepiandrosterone sulfotransferase. Purification, molecular cloning, and characterization, " Annals of the New York Academy of Sciences, vol. 774, pp. 59-72, 1995.
25. Y. Alnouti, "Bile acid sulfation: A pathway of bile acid elimination and detoxification, " Toxicological Sciences, vol. 108, no. 2, pp. 225-246, 2009.
26. A. F. Hofmann, "Detoxification of lithocholic acid, a toxic bile-Acid: relevance to drug hepatotoxicity, " Drug Metabolism Reviews, vol. 36, no. 3-4, pp. 703-722, 2004.
27. H.-L. Fang, S. C. Strom, E. Ellis et al., "Positive and negative regulation of human hepatic hydroxysteroid sulfotransferase (SULT2A1) gene transcription by rifampicin: roles of hepatocyte nuclear factor 4 and pregnane X receptor, " Journal of Pharmacology and ExperimentalTherapeutics, vol. 323, no.2, pp. 586-598, 2007.
28. E. V. Loftus Jr., G. C. Harewood, C. G. Loftus et al., "PSC-IBD: A unique form of inflammatory bowel disease associated with primary sclerosing cholangitis, " Gut, vol. 54, no. 1, pp. 91-96, 2005.
29. E. Seki and D. A. Brenner, "Recent advancement of molecular mechanisms of liver fibrosis, " Journal of Hepato-Biliary-Pancreatic Sciences, 2015.
30. L. EkstrOm and A. Rane, "Genetic variation, expression and ontogeny of sulfotransferase SULT2A1 in humans, " The Pharmacogenomics Journal, 2015.